Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.19% on August 8, reaching $2.105 per share, with a total market capitalization of $84.8785 million [1] - As of June 30, 2024, the company reported total revenue of $1 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] - The company is focused on developing novel cancer therapies, particularly advanced tumor immunotherapy, and aims to transform cancer treatment through its unique academic and business capabilities [1] Financial Performance - Total revenue for the fiscal year ending June 30, 2024, is projected at $1 million, marking a 14.29% increase year-over-year [1] - The net profit attributable to shareholders is reported at -$7.262 million, which is a 42.91% increase in losses compared to the previous year [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company established in 2013, headquartered in the United States [1] - The company specializes in the research and development of new cancer therapies, including treatments for non-small cell lung cancer and the prevention of neutropenia [1] - The main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers [1] - BeyondSpring employs a novel, highly scalable business model that integrates resources from the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1]

Group 1 - The stock price of BeyondSpring Inc. (BYSI) increased by 5.07% on August 6, reaching $2.154 per share, with a total market capitalization of $86.8373 million [1] - As of June 30, 2024, BeyondSpring reported total revenue of $1.0 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a year-over-year increase of 42.91% [1] Group 2 - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers, with a novel, scalable business model aimed at efficient and low-cost drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]

大事提醒： 5月5日，万春医药将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实 际披露日期以公司公告为准）。 作者：行情君 财务数据显示，截至2024年06月30日，万春医药收入总额100.0万美元，同比增长14.29%；归母净利 润-726.2万美元，同比增长42.91%。 资料显示，万春药业公司是一家处于全球临床阶段的生物制药公司,专注于新型癌症疗法,包括晚期肿瘤 免疫药物的研发。在BeyondSpring,他们的使命是利用他们癌症治疗的学术及业务能力,采用独有方式来 改变癌症治疗的现状。公司成立于2013年,总部设立在美国。他们的主要项目普那布林来源于天然化合 物,由于所具有的各种生化活性,对多种癌症有治疗潜力。他们采用一种新颖的、高度可扩展的商业模式, 整合美中优势资源,高效、低成本地实现药物的报批和开发。目标研究领域包括:非小细胞肺癌、中性粒 细胞减少症的预防和普那布林+PD-1单抗。 8月6日，万春医药(BYSI)盘中上涨3.41%，截至22:48，报2.12美元/股，成交4133.0美元，总市值8547.06 万美元。 本文源自：金融界 ...

资料显示，万春药业公司是一家处于全球临床阶段的生物制药公司,专注于新型癌症疗法,包括晚期肿瘤 免疫药物的研发。在BeyondSpring,他们的使命是利用他们癌症治疗的学术及业务能力,采用独有方式来 改变癌症治疗的现状。公司成立于2013年,总部设立在美国。他们的主要项目普那布林来源于天然化合 物,由于所具有的各种生化活性,对多种癌症有治疗潜力。他们采用一种新颖的、高度可扩展的商业模式, 整合美中优势资源,高效、低成本地实现药物的报批和开发。目标研究领域包括:非小细胞肺癌、中性粒 细胞减少症的预防和普那布林+PD-1单抗。 本文源自：金融界 作者：行情君 8月5日，万春医药(BYSI)开盘上涨4.35%，截至21:30，报2.16美元/股，成交4.29万美元，总市值8708.33 万美元。 财务数据显示，截至2024年06月30日，万春医药收入总额100.0万美元，同比增长14.29%；归母净利 润-726.2万美元，同比增长42.91%。 大事提醒： 5月5日，万春医药将披露2024财年年报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实 际披露日期以公司公告为准）。 ...

Group 1 - The stock price of BeyondSpring Inc. (BYSI) increased by 5.8% on August 4, reaching $2.19 per share, with a total market capitalization of $88.29 million [1] - As of June 30, 2024, BeyondSpring reported total revenue of $1.00 million, representing a year-over-year growth of 14.29%, while the net profit attributable to the parent company was -$7.26 million, showing a year-over-year increase of 42.91% [1] - BeyondSpring is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] Group 2 - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [1] - BeyondSpring's main project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] - The company employs a novel, highly scalable business model that integrates resources from the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 3.38% on August 4, reaching $2.14 per share, with a total market capitalization of approximately $86.28 million [1] - As of June 30, 2024, the company reported total revenue of $1.00 million, reflecting a year-over-year growth of 14.29%, while the net loss attributable to shareholders was $7.26 million, which represents a 42.91% increase compared to the previous year [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [2] - The company was founded in 2013 and is headquartered in the United States, with a mission to transform cancer treatment through its academic and business capabilities [2] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [2] - BeyondSpring employs a novel, highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [2] - Target research areas include non-small cell lung cancer, prevention of neutropenia, and Plinabulin combined with PD-1 monoclonal antibodies [2]

Core Insights - BeyondSpring Pharmaceuticals (BYSI) experienced a stock price increase of 2.22%, reaching $2.075 per share, with a total market capitalization of $83.6564 million as of August 1 [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of $1 million, reflecting a year-over-year growth of 14.29%, while the net profit attributable to shareholders was -$7.262 million, showing a 42.91% increase in losses compared to the previous year [1] - The company is set to release its fiscal year 2024 annual report on May 5, with the actual disclosure date subject to company announcements [1] Company Overview - BeyondSpring Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, including advanced tumor immunotherapy [1] - Established in 2013 and headquartered in the United States, the company aims to leverage its academic and business expertise in cancer treatment to transform the current landscape of cancer therapy [1] - The primary project, Plinabulin, is derived from natural compounds and has therapeutic potential for various cancers due to its biochemical activities [1] Business Model and Research Focus - The company employs an innovative and highly scalable business model that integrates resources from both the U.S. and China to efficiently and cost-effectively achieve drug approval and development [1] - Key research areas include non-small cell lung cancer, prevention of neutropenia, and the combination of Plinabulin with PD-1 monoclonal antibodies [1]

FLORHAM PARK, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) today announced publication of a human clinical study in Med (Cell Press) demonstrating that Plinabulin, when combined with radiation and a checkpoint inhibitor, induces dendritic cell (DC) maturation and elicits tumor responses in patients across multiple cancer types who had failed prior ICI therapy. The study also identified a potential biomarker—baseline GEF-H1 immune signature—that may enable patient pre-selection an ...

Plinabulin's Mechanism and Preclinical Evidence - Plinabulin is a unique tubulin binder with a distinct binding site compared to other tubulin-binding agents[16, 21] - Preclinical studies show that Plinabulin, combined with radiation and anti-PD-1, activates dendritic cells (DCs), stimulates T-cell proliferation, and achieves abscopal effects[17, 24] - Plinabulin induces DC maturation, especially when administered after irradiation (IR), and Plinabulin-treated DCs stimulate T cell proliferation, enhanced by combining with IR[25] Clinical Efficacy and Immune Activation - In a Phase 1 study, the Plinabulin triple combination (with radiation and PD-1/PD-L1 inhibitors) led to an 80% disease control rate (DCR) in 10 IO-refractory patients[18, 32] - Durable responses were observed in 2 Hodgkin lymphoma patients who progressed after 12 or 16 prior lines of therapy[33] - Responding patients exhibited early immune activation with DC maturation and proinflammatory monocytes in the peripheral blood across six different cancer types[19, 35] Summary and Future Directions - Plinabulin demonstrates induction of DC maturation and re-sensitization to anti-PD(L)1 in IO-refractory tumors[37] - The impressive overall results, showing a high 80% disease control rate in ICI-refractory and heavily pre-treated patients, warrant further clinical studies of Plinabulin/IO combinations in IO-refractory settings[37, 38]

Median PFS at 6.8 months, Disease Control Rate of 77.3%, 15 months OS% at 78% in Metastatic NSCLC Patients after Progression on PD-1/L1 Therapies Median Progression-Free Survival (PFS): 6.8 months — nearly double the 3.7 months seen with current standard of care (SOC) docetaxel Confirmed Objective Response Rate (ORR): 18.2% — higher than the 12.8% seen with SOC docetaxel Disease Control Rate (DCR: PR + SD > 4 months): 77.3% — indicating clinical benefit majority of patients who progressed on prior PD-1/L1 i ...